Manila Times Business
Ascletis Reinforces Its Differentiated Obesity Portfolio at American Diabetes Association (ADA) 2026 Scientific Sessions, Showcasing ASC30 Clinical Data and Exciting Preclinical Findings from ASC37 and ASC39
HONG KONG, June 8, 2026 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces the presentation of three key studies at the American Diabetes Association (ADA) 2026 Scientific Sessions (taking place June 5-8, 2026, in New Orleans, Louisiana), highlighting its differentiated portfolio in obesity treatment, including small-molecule candidates, a peptide therapeutic, and an oral peptide delivery-enhancing technology. The data attracted considerable interest from leading experts at
This is an excerpt. Read the full article at the original source:
Source: manilatimes.net
Read Full Article on manilatimes.net →More from Manila Times Business
Committed to care: How medical services sustain navy readiness
2h ago
GIGABYTE Announces AERO X16 Now Available, Bringing Next-Gen AI Performance to an Ultra-Thin Copilot+ PC
2h ago
The Shilla Seoul Hosts South Korea's First LHW Asia-Pacific Membership Meeting
2h ago
Voltalia SA: Total number of shares and voting rights in the share capital as of May 31, 2026
2h ago